{"id":56497,"date":"2026-02-06T20:54:08","date_gmt":"2026-02-06T12:54:08","guid":{"rendered":"https:\/\/flcube.com\/?p=56497"},"modified":"2026-02-06T20:54:09","modified_gmt":"2026-02-06T12:54:09","slug":"give-kids-a-chance-act-extends-fda-pediatric-research-authority-and-prv-program","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=56497","title":{"rendered":"Give Kids a Chance Act Extends FDA Pediatric Research Authority and PRV Program"},"content":{"rendered":"\n<p>The <strong>US Congress<\/strong> has introduced the <strong>Give Kids a Chance Act<\/strong>, legislation aimed at broadening the <strong>Food and Drug Administration&#8217;s (FDA)<\/strong> authority over rare pediatric disease research. The bill modifies requirements for molecularly targeted pediatric cancer investigations, extends the <strong>Priority Review Voucher (PRV)<\/strong> program until <strong>September\u202f30,\u202f2029<\/strong>, and reauthorizes <strong>National Institutes of Health (NIH)<\/strong> funding through <strong>Fiscal Year\u202f2027<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-key-legislative-provisions\">Key Legislative Provisions<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Provision<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Bill Name<\/strong><\/td><td>Give Kids a Chance Act<\/td><\/tr><tr><td><strong>Target Agency<\/strong><\/td><td>FDA<\/td><\/tr><tr><td><strong>Pediatric Cancer Research<\/strong><\/td><td>Permits research on new drugs in combination with approved active ingredients under specified conditions<\/td><\/tr><tr><td><strong>Enforcement Authority<\/strong><\/td><td>FDA may take action against sponsors failing to comply with pediatric study requirements due to lack of due diligence<\/td><\/tr><tr><td><strong>PRV Program Extension<\/strong><\/td><td>Extended until September\u202f30,\u202f2029 (originally sunset December\u202f20,\u202f2024)<\/td><\/tr><tr><td><strong>PRV Mechanism<\/strong><\/td><td>Approval for rare pediatric disease drug qualifies for voucher redeemable for priority review of different product; transferable\/sellable<\/td><\/tr><tr><td><strong>NIH Funding<\/strong><\/td><td>Reauthorized through Fiscal Year\u202f2027 for priority pediatric research<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-impact-amp-strategic-implications\">Market Impact &amp; Strategic Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Pediatric Oncology Pipeline:<\/strong> Combination therapy provision accelerates development of novel regimens for rare pediatric cancers, addressing <strong>~15%<\/strong> of childhood cancers with molecular targets<\/li>\n\n\n\n<li><strong>PRV Market Value:<\/strong> Extended program maintains <strong>$100\u2013150\u202fmillion<\/strong> voucher market value; incentivizes investment in rare pediatric disease R&amp;D<\/li>\n\n\n\n<li><strong>Regulatory Compliance:<\/strong> Enhanced enforcement authority ensures sponsors demonstrate due diligence, reducing delays in pediatric study completion<\/li>\n\n\n\n<li><strong>NIH Funding Stability:<\/strong> FY\u202f2027 reauthorization provides <strong>$2\u20133\u202fbillion<\/strong> annual funding certainty for pediatric research infrastructure<\/li>\n\n\n\n<li><strong>Industry Response:<\/strong> Biotech and pharma trade associations support extension; rare disease advocacy groups praise combination therapy flexibility<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding legislative implementation timelines, regulatory enforcement patterns, and market impacts of the Give Kids a Chance Act. Actual outcomes may differ due to congressional approval processes, FDA rulemaking, and industry adaptation.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>The US Congress has introduced the Give Kids a Chance Act, legislation aimed at broadening&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[4],"tags":[24],"class_list":["post-56497","post","type-post","status-publish","format-standard","hentry","category-policy-regulatory","tag-rare-orphan-disease-drugs"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Give Kids a Chance Act Extends FDA Pediatric Research Authority and PRV Program - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"The US Congress has introduced the Give Kids a Chance Act, legislation aimed at broadening the Food and Drug Administration&#039;s (FDA) authority over rare pediatric disease research. The bill modifies requirements for molecularly targeted pediatric cancer investigations, extends the Priority Review Voucher (PRV) program until September\u202f30,\u202f2029, and reauthorizes National Institutes of Health (NIH) funding through Fiscal Year\u202f2027.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=56497\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Give Kids a Chance Act Extends FDA Pediatric Research Authority and PRV Program\" \/>\n<meta property=\"og:description\" content=\"The US Congress has introduced the Give Kids a Chance Act, legislation aimed at broadening the Food and Drug Administration&#039;s (FDA) authority over rare pediatric disease research. The bill modifies requirements for molecularly targeted pediatric cancer investigations, extends the Priority Review Voucher (PRV) program until September\u202f30,\u202f2029, and reauthorizes National Institutes of Health (NIH) funding through Fiscal Year\u202f2027.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=56497\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-02-06T12:54:08+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-02-06T12:54:09+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56497#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56497\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Give Kids a Chance Act Extends FDA Pediatric Research Authority and PRV Program\",\"datePublished\":\"2026-02-06T12:54:08+00:00\",\"dateModified\":\"2026-02-06T12:54:09+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56497\"},\"wordCount\":300,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Rare \\\/ orphan disease drugs\"],\"articleSection\":[\"Policy \\\/ Regulatory\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=56497#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56497\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=56497\",\"name\":\"Give Kids a Chance Act Extends FDA Pediatric Research Authority and PRV Program - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-02-06T12:54:08+00:00\",\"dateModified\":\"2026-02-06T12:54:09+00:00\",\"description\":\"The US Congress has introduced the Give Kids a Chance Act, legislation aimed at broadening the Food and Drug Administration's (FDA) authority over rare pediatric disease research. The bill modifies requirements for molecularly targeted pediatric cancer investigations, extends the Priority Review Voucher (PRV) program until September\u202f30,\u202f2029, and reauthorizes National Institutes of Health (NIH) funding through Fiscal Year\u202f2027.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56497#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=56497\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56497#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Give Kids a Chance Act Extends FDA Pediatric Research Authority and PRV Program\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Give Kids a Chance Act Extends FDA Pediatric Research Authority and PRV Program - Insight, China&#039;s Pharmaceutical Industry","description":"The US Congress has introduced the Give Kids a Chance Act, legislation aimed at broadening the Food and Drug Administration's (FDA) authority over rare pediatric disease research. The bill modifies requirements for molecularly targeted pediatric cancer investigations, extends the Priority Review Voucher (PRV) program until September\u202f30,\u202f2029, and reauthorizes National Institutes of Health (NIH) funding through Fiscal Year\u202f2027.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=56497","og_locale":"en_US","og_type":"article","og_title":"Give Kids a Chance Act Extends FDA Pediatric Research Authority and PRV Program","og_description":"The US Congress has introduced the Give Kids a Chance Act, legislation aimed at broadening the Food and Drug Administration's (FDA) authority over rare pediatric disease research. The bill modifies requirements for molecularly targeted pediatric cancer investigations, extends the Priority Review Voucher (PRV) program until September\u202f30,\u202f2029, and reauthorizes National Institutes of Health (NIH) funding through Fiscal Year\u202f2027.","og_url":"https:\/\/flcube.com\/?p=56497","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-02-06T12:54:08+00:00","article_modified_time":"2026-02-06T12:54:09+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=56497#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=56497"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Give Kids a Chance Act Extends FDA Pediatric Research Authority and PRV Program","datePublished":"2026-02-06T12:54:08+00:00","dateModified":"2026-02-06T12:54:09+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=56497"},"wordCount":300,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Rare \/ orphan disease drugs"],"articleSection":["Policy \/ Regulatory"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=56497#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=56497","url":"https:\/\/flcube.com\/?p=56497","name":"Give Kids a Chance Act Extends FDA Pediatric Research Authority and PRV Program - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-02-06T12:54:08+00:00","dateModified":"2026-02-06T12:54:09+00:00","description":"The US Congress has introduced the Give Kids a Chance Act, legislation aimed at broadening the Food and Drug Administration's (FDA) authority over rare pediatric disease research. The bill modifies requirements for molecularly targeted pediatric cancer investigations, extends the Priority Review Voucher (PRV) program until September\u202f30,\u202f2029, and reauthorizes National Institutes of Health (NIH) funding through Fiscal Year\u202f2027.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=56497#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=56497"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=56497#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Give Kids a Chance Act Extends FDA Pediatric Research Authority and PRV Program"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/56497","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=56497"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/56497\/revisions"}],"predecessor-version":[{"id":56498,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/56497\/revisions\/56498"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=56497"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=56497"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=56497"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}